

May 17, 2023

Listing Department Code: 531 335

BSE LIMITED

P J Towers, Dalal Street, Fort, Mumbai–400 001

Listing Department Code: ZYDUSWELL

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E),

Mumbai-400 051

Sub: <u>Appointment / Re-appointment of Independent Directors, Twenty Ninth Annual</u>
General Meeting, Record Date and payment of Dividend

Ref.: <u>Intimation under regulation 30 and 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")</u>

Dear Sir / Madam,

The Board of Directors at their meeting held today i.e. May 17, 2023, has inter alia approved the following:

- 1. Based on the recommendation of Nomination and Remuneration Committee and subject to approval of members by way of special resolution, approved:
 - the appointment of Mr. Akhil Monappa (DIN: 09784366) as an Additional Director (Non-Executive & Independent Director) of the Company for the first term of 5 (five) consecutive years with effect from May 17, 2023 to May 16, 2028, not liable to retire by rotation.
 - the re-appointment of Ms. Dharmishtaben N. Raval (DIN: 02792246) as an Independent Director of the Company for the second term of 5 (five) consecutive years with effect from March 11, 2024 upto March 10, 2029, not liable to retire by rotation.
 - the re-appointment of Mr. Srivishnu R. Nandyala (DIN: 00025063) as an Independent Director of the Company for the second term of 5 (five) consecutive years with effect from March 11, 2024 upto March 10, 2029, not liable to retire by rotation.

Necessary details as prescribed in SEBI Circular dated September 9, 2015 are provided in **Annexure-"A"**.

Zydus Wellness Limited

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.



- 2. Twenty Ninth Annual General Meeting of the members of the Company is scheduled to be held on Thursday, August 3, 2023 through Video Conference / Other Audio Visual Means.
- 3. The Board of Directors at their meeting held today i.e. May 17, 2023, have recommended Final Dividend of ₹ 5.00/- (@ 50%) per equity share of ₹ 10/- each, subject to approval of the members at the ensuing Annual General Meeting scheduled to be held on August 3, 2023.
 - In compliance with regulation 42(1) of the Listing Regulations, the Record Date has been fixed as Friday, July 21, 2023 to determine the list of members entitled to receive the Final Dividend for the financial year 2022-23, recommended by the Board of Directors subject to the approval of the same by the members at the ensuing Annual General Meeting.
- 4. The Company shall make the payment of dividend, subject to deduction of tax at source, on or after August 8, 2023 subject to the approval of the same by the members at the ensuing Annual General Meeting scheduled to be held on August 3, 2023.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **ZYDUS WELLNESS LIMITED**

NANDISH P. JOSHI COMPANY SECRETARY

Encl.: As above

Zydus Wellness Limited

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.



Annexure-"A"

Name of Director	Mr. Akhil Monappa (DIN: 09784366)
Reason for change (appointment)	Appointed as an Additional Director (Non-Executive & Independent Director) of the Company.
Date of appointment and	May 17, 2023
Terms of appointment	For a period of 5 (five) consecutive years w.e.f. May 17, 2023 to May 16, 2028, subject to approval of members by way of special resolution and he will not be liable to retire by rotation.
	He will be entitled to receive sitting fees for attending the Board and committee meetings and commission/remuneration as may be decided by the Board of Directors.
Disclosure of relationship between Directors	He is not related to any Director of the Company.
Brief profile	Mr. Akhil Monappa has a MBA and MPA-ID degree from Harvard University, Cambridge, USA and a Bachelor's degree in Science in Electrical Engineering from Georgia Tech, Atlanta, USA.
	He has a background in technology both in Investing as well as Operating roles. Currently he is a Director of YAZZ Limited and Zydus Lifesciences Limited, the holding Company and active investor in public and private companies. Previously, he was a Partner in the Technology Group at Generation Investment Management in London, a sustainability focused fund where he invested in global tech companies and advised company boards and management on matters of strategy, capital allocation, and governance. Prior to that, he was at Atlas Venture in London where he invested in early stage technology companies providing both board level and operational expertise. Early in his career, he was an operating executive at C-Bridge

Zydus Wellness Limited

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.

Phone No.: +91-79-71800000; Website: www.zyduswellness.com

CIN: L15201GJ1994PLC023490



	Internet Solutions in Cambridge, USA where he was responsible for go to market partnerships with some of the world's leading technology companies as well as held various pre-sales and technical roles.
Declaration	In accordance with SEBI letter dated June 14, 2018 read along with BSE circular dated June 20, 2018, we confirm that Mr. Akhil Monappa is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority.

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.



Name of Director	Ms. Dharmishtaben N. Raval (DIN: 02792246)
Reason for change (re-appointment)	Re-appointed as an Independent Director of the Company.
Date of re-appointment and	March 11, 2024
Terms of re-appointment	For the second term of 5 (five) consecutive years with effect from March 11, 2024 upto March 10, 2029, subject to approval of members by way of special resolution and she will not be liable to retire by rotation.
	She will be entitled to receive sitting fees for attending the Board and committee meetings and commission/ remuneration as may be decided by the Board of Directors.
Disclosure of relationship between Directors	She is not related to any Director of the Company.
Brief profile	Ms. Dharmishtaben N. Raval an eminent lawyer, is a science graduate and master in Commercial Laws. She enrolled as an Advocate of the Gujarat Bar Association in 1980. She has worked extensively with late Mr. Kirit N. Raval, former Solicitor General of India. She has exposure in the matters of various laws, such as Service Laws, Banking Laws, Company Law, Labour Laws, Income Tax Laws and SEBI Laws. She has also worked as an Executive Director - Legal in SEBI till May, 2003 and thereafter she started her practice as an Advocate at Gujarat High Court. She was a Senior Standing Counsel for the Central Government for the Gujarat High Court till June, 2004. She was a member of the High Powered Advisory Committee of SEBI and is presently on the Mutual Fund Advisory Committee of SEBI. She is presently practising at the Gjujarat High Court and at NCLT Ahmedabad. She is empanelled as Panel Advocates with institutions like – UTI, SBI, SEBI, GPCB and IRDA.

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.



Declaration	In accordance with SEBI letter dated June 14, 2018 read along with BSE circular dated June 20, 2018, we
	confirm that Ms. Dharmishtaben N. Raval is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such
	authority.

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.



Name of Director	Mr. Srivishnu R. Nandyala (DIN: 00025063)
Reason for change (re-appointment)	Re-appointed as an Independent Director of the Company.
Date of re-appointment and	March 11, 2024
Terms of re-appointment	For the second term of 5 (five) consecutive years with effect from March 11, 2024 upto March 10, 2029, subject to approval of members by way of special resolution and he will not be liable to retire by rotation.
	He will be entitled to receive sitting fees for attending the Board and committee meetings and commission/remuneration as may be decided by the Board of Directors.
Disclosure of relationship between Directors	He is not related to any Director of the Company.
Brief profile	Mr. Srivishnu R. Nandyala is the Chairman and CEO of Exciga group. Exciga group is a group of Investment Companies that invests in the Financial Markets and Real Estate with zero debt and no outside money. In the past he was a Promoter Director in Raasi Cements and Raasi Ceramics. He is an Independent Director in Amara Raja Batteries Limited and Heritage Foods Limited.
	He has a bachelor's degree in Engineering from Osmania University and the Owner President Management Program from Harvard Business School. He is an avid fitness and adventure enthusiast and has cycled 9 countries across Europe a distance of 1250 kms approximately.
Declaration	In accordance with SEBI letter dated June 14, 2018 read along with BSE circular dated June 20, 2018, we confirm that Mr. Srivishnu R. Nandyala is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority.

(a subsidiary of Zydus Lifesciences Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.